However, RBC Capital has reiterated that Vertex could require stronger execution to adopt Alyftrek to justify the current ...

Fintel reports that on June 16, 2025, Piper Sandler initiated coverage of Vertex (NasdaqGM:VERX) with a Overweight ...

Vertex Pharmaceuticals (NASDAQ:VRTX) has posted new data from a Phase 1/2/3 study for zimislecel (VX-880), its experimental ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

Vertex Pharmaceuticals has been making quiet waves lately, popping up on investors’ radars like a biotech whack-a-mole. With ...

RBC Capital slightly trimmed Vertex Pharmaceuticals’ price target from $423 to $420, but the firm’s rating stayed the course.

This algorithm has quadratic run time so it can be slow with large profiles ... with many edges meeting at each polygon vertex. The result is an alternation of flat triangular faces with conical ...

In the course of constructing trigonometric solutions of YBE, Kulish and Reshetikhin 141) introduced a deformation of the universal enveloping algebra of sl(2). In the reprint [11] Sklyanin defines an ...